Usted buscó: dreifitöflur (Islandés - Inglés)

dreifitöflur
dispersible tablets

exjade 125 mg dreifitöflur
exjade 125 mg dispersible tablets

56 dreifitöflur (14 x 4)
56 dispersible tablets (14 x 4)

exjade 125 mg dreifitöflur deferasirox
exjade 125 mg dispersible tablets deferasirox

exjade er fáanlegt sem dreifitöflur.
exjade is supplied as dispersible tablets.

deferasirox er einnig til sem dreifitöflur.
deferasirox also comes as “dispersible” tablets.

eu/1/06/356/001 28 dreifitöflur
eu/1/06/356/001 28 dispersible tablets

taktu votubia dreifitöflur einu sinni á sólarhring.
take votubia dispersible tablets once a day.

notið votubia dreifitöflur einungis sem mixtúru, dreifu
take votubia dispersible tablets as an oral suspension only

exjade filmuhúðaðar töflur hafa meira aðgengi en exjade dreifitöflur.
exjade film-coated tablets demonstrate higher bioavailability compared to the exjade dispersible tablet formulation.

ekki hætta að taka votubia dreifitöflur nema læknirinn segi þér að gera það.
do not stop taking votubia dispersible tablets unless your doctor tells you to.

votubia 2 mg dreifitöflur eu/1/11/710/009-011
votubia 2 mg dispersible tablets eu/1/11/710/009-011

exjade 125 mg dreifitöflur exjade 250 mg dreifitöflur exjade 500 mg dreifitöflur deferasirox
exjade 125 mg dispersible tablets exjade 250 mg dispersible tablets exjade 500 mg dispersible tablets deferasirox

fletti-þrýstiþynnur sem innihalda 14 dreifitöflur, öskjur innihalda 56 dreifitöflur.
peel-push blisters containing 14 dispersible tablets; cartons contain 56 dispersible tablets.

tracleer 32 mg dreifitöflur innihalda aspartam (e951) sem breytist í fenýlalanín.
tracleer 32 mg dispersible tablets contain a source of phenylalanine (aspartame – e951).

fimmtíuogsex sjúklingar yngri en 6 ára tóku þátt í lykilrannsókninni og 28 þeirra fengu deferasirox dreifitöflur.
fifty-six patients under the age of 6 years participated in this pivotal study, 28 of them receiving deferasirox dispersible tablets.

ef þú ert að skipta af meðferð með filmuhúðuðum töflum yfir á þessar dreifitöflur þarf að breyta skammtinum hjá þér.
if you are switching from the film-coated tablets to these dispersible tablets, you will need an adjustment of the dose.

votubia 2 mg dreifitöflur eru hvítar eða fölgular, kringlóttar, flatar töflur með sniðbrún, án deiliskoru.
votubia 2 mg dispersible tablets are white to slightly yellowish, round, flat tablets with a bevelled edge and no score.

að auki verður sérstakt bréf sent læknum og lyfjafræðingum með upplýsingum um hvenær exjade dreifitöflur verða teknar af markaði í evrópu.
additionally, prescribers and pharmacists will be informed via a specific letter regarding the timelines for removing exjade dispersible tablets from the eu market.

heildaraðgengi (auc) deferasirox (sem dreifitöflur) er um 70% samanborð við gjöf í bláæð.
the absolute bioavailability (auc) of deferasirox (dispersible tablet formulation) is about 70% compared to an intravenous dose.